TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of General Internal Medicine
Division of Hematology & Oncology
Division of General Surgery
National Taiwan University Cancer Center
(在職)
Division of General Internal Medicine
Division of Hematology & Oncology
更新時間：2025-03-10
鄭安理Cheng, Ann-Lii
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
48Publications
1
Ryoo BY, Cheng AL, Ren Z, Kim TY, Pan H, Rau KM, Choi HJ, Park JW, Kim JH, Yen CJ, Lim HY, Zhou D, Straub J, Scheele J, Berghoff K, Qin S. Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. Br J Cancer. 2021 Jul;125(2):200-208. doi: 10.1038/s41416-021-01380-3. Epub 2021 May 10. PMID: 33972742; PMCID: PMC8292411.
2
Ma WL, Yeh KH, Yao M, Tang JL, Lin CW, Wang YT, Yeh YC, Wang HP, Cheng AL, Kuo SH. Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas. J Formos Med Assoc. 2021 Jan;120(1 Pt 2):293-302. doi: 10.1016/j.jfma.2020.10.001. Epub 2020 Oct 21. PMID: 33289640.
3
Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, Kudo M. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. Cancer. 2021 Mar 15;127(6):865-874. doi: 10.1002/cncr.33317. Epub 2020 Nov 24. PMID: 33231873.
4
Kasper S, Foch C, Messinger D, Esser R, Lamy FX, Rothe V, Chen W, Cheng AL, Rouyer M, Brodowicz T, Zielinski C. Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2021 Feb;144:291-301. doi: 10.1016/j.ejca.2020.11.013. Epub 2020 Dec 28. PMID: 33383349.
5
Shao YY, Cheng AL, Hsu CH. An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. Oncologist. 2021 May;26(5):422-426. doi: 10.1002/onco.13755. Epub 2021 Mar 20. PMID: 33687750; PMCID: PMC8100545.
6
Cheng AL. Pursuing efficacious systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):95-96. doi: 10.1038/s41575-020-00405-1. PMID: 33408363.
7
Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2020 Sep 15;26(18):4795-4804. doi: 10.1158/1078-0432.CCR-19-3884. Epub 2020 Jul 7. PMID: 32636319; PMCID: PMC7779341.
8
Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020 Dec;73(6):1460-1469. doi: 10.1016/j.jhep.2020.07.026. Epub 2020 Jul 22. PMID: 32710922; PMCID: PMC7751218.
9
Lin ZZ, Chen BB, Hung YP, Huang PH, Shen YC, Shao YY, Hsu CH, Cheng AL, Lee RC, Chao Y, Hsu C. A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. Oncologist. 2020 Sep;25(9):e1280-e1285. doi: 10.1634/theoncologist.2020-0143. Epub 2020 Apr 9. PMID: 32271494; PMCID: PMC7485356.
10
Tsai MS, Chang SH, Kuo WH, Kuo CH, Li SY, Wang MY, Chang DY, Lu YS, Huang CS, Cheng AL, Lin CH, Chen PC. A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women. Environ Int. 2020 Sep;142:105850. doi: 10.1016/j.envint.2020.105850. Epub 2020 Jun 21. PMID: 32580117.
